Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients With Metastatic Castration Resistant Prostate Cancer Treated With With Life Prolonging Therapies: A Pilot Study
Overview
- Phase
- Phase 2
- Intervention
- 18F-fluciclovine PET Scan
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Sponsor
- Tulane University
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies
- Status
- Completed
- Last Updated
- 7 months ago
Overview
Brief Summary
This is a pilot phase 2 single-arm study, of men with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with any of the approved life-prolonging therapies: abiraterone 1000 mg daily plus prednisone 5 mg (or dexamethasone 0.5 mg) daily, enzalutamide 160 mg daily, or docetaxel 50 mg/m2 every two weeks or 75 mg/m2 every three weeks.
Detailed Description
Prostate cancer is a hormonally-driven disease and androgens are key in the growth of both normal prostate and prostate cancer cells. Once mCRPC is evident, most patients receive a second-generation hormonal therapy to further suppress the synthesis or androgens (abiraterone) and to block androgen receptor (AR) activation, nuclear translocation and DNA binding (enzalutamide). Conventional imaging of prostate cancer has limitations in staging, restaging after biochemical relapse, and response assessment. Functional imaging with positron emission tomography (PET) can target various aspects of tumor biology and is clearly superior in the detection of extra-prostatic disease. 18F-fluciclovine is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters that are upregulated in prostate cancer cells. 18F-fluciclovine is approved for PET imaging to identify sites of prostate cancer recurrence in men with rising prostate specific antigen (PSA) following prior definitive treatment. This study describes the changes in 18F-fluciclovine PET scan and compare these results with PSA and conventional computerized tomography (CT) and bone scans, in mCRPC patients treated with abiraterone acetate-prednisone, enzalutamide or docetaxel.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eastern Cooperative Oncology Group (ECOG) Performance status 0-2;
- •Age ≥ 18 years;
- •Histologically confirmed adenocarcinoma of the prostate;
- •Ongoing use of luteinizing hormone-releasing hormone (LHRH) required in the absence of surgical castration and castrate concentration of testosterone (\< 50 ng/dL);
- •Detectable PSA of at least 2 ng/dL;
- •Metastatic disease documented by CT or bone scan within 42 days of cycle 1 day 1;
- •Life expectancy of ≥ 6 months;
- •Must have disease progression despite a castrate concentration of testosterone of \< 50 ng/dL based on:
- •A. PSA progression defined as increase in PSA of at least 2 ng/dL and 25% from nadir values of prior therapy, determined by 2 separate measurement taken at least 1 week apart;
- •B. Radiographic disease progression based on response evaluation criteria in solid tumors (RECIST) 1.1 for soft tissue disease and/or prostate cancer working group 3 (PCWG3) for bone only disease;
Exclusion Criteria
- •Pathological findings consistent with small cell carcinoma of the prostate;
- •Prior treatment with docetaxel for metastatic castration-resistant prostate cancer (CRPC);
- •Patient with normal 18F-flucicolovine PET/CT scans at baseline;
- •Know allergies, hypersensitivity, or intolerance to abiraterone, prednisone, 18F-fluciclovine or their excipients;
- •Any chronic medical condition requiring ≥ 10 mg daily of systemic prednisone (or equivalent);
- •Major surgery (e.g., required general anesthesia) within 2 weeks before screening;
- •Uncontrolled active infection (including hepatitis B or C or AIDS). Patients with hepatitis B/C who have disease under control and no significant liver function impairment, and undetectable viral load will be allowed to participate. Similarly, patients with known HIV and ≥ 400 CD4 + T cells are allowed to participate;
- •Evidence of other metastatic malignancies within the last year;
- •Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
Arms & Interventions
18F-fluciclovine PET Scan
Single intravenous administration of 18F-fluciclovine for PET Scan.
Intervention: 18F-fluciclovine PET Scan
Outcomes
Primary Outcomes
Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies
Time Frame: 12 weeks
To describe the 18F-fluciclovine PET findings for patients with mCRPC prior to starting treatment with Life Prolonging Therapies, and at 12 weeks after Life Prolonging Therapies treatment initiation. We have 4 categories that can be seen in the scan to measure the metabolic response using PERSIST 1.1, 1)stable disease, 2)progressive disease, 3)partial response and 4)complete response.
PET Scan vs. Conventional CT and Bone Scan
Time Frame: 12 weeks
A comparison of 18F-fluciclovine PET with conventional CT and bone scans for patients with mCRPC prior to starting treatment with life prolonging therapies, and at 12 weeks after starting life prolonging therapies; and to correlate these changes with PSA response and progression after starting life prolonging therapies.